Goldman Sachs’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-83,119
| Closed | -$277K | – | 5723 |
|
|
2019
Q4 | $277K | Sell |
83,119
-112
| -0.1% | -$356 | ﹤0.01% | 4783 |
|
|
2019
Q3 | $253K | Buy |
83,231
+57,261
| +220% | +$161K | ﹤0.01% | 4746 |
|
|
2019
Q2 | $62K | Sell |
25,970
-13,716
| -35% | -$41K | ﹤0.01% | 5002 |
|
|
2019
Q1 | $149K | Sell |
39,686
-1,041
| -3% | -$3.9K | ﹤0.01% | 4863 |
|
|
2018
Q4 | $146K | Buy |
40,727
+15,646
| +62% | +$68K | ﹤0.01% | 4917 |
|
|
2018
Q3 | $144K | Sell |
25,081
-6,858
| -21% | -$39.2K | ﹤0.01% | 5016 |
|
|
2018
Q2 | $160K | Sell |
31,939
-6,198
| -16% | -$31.9K | ﹤0.01% | 5068 |
|
|
2018
Q1 | $196K | Sell |
38,137
-1,048
| -3% | -$6.31K | ﹤0.01% | 5019 |
|
|
2017
Q4 | $236K | Sell |
39,185
-86,251
| -69% | -$519K | ﹤0.01% | 5328 |
|
|
2017
Q3 | $696K | Sell |
125,436
-844
| -0.7% | -$4.36K | ﹤0.01% | 4867 |
|
|
2017
Q2 | $586K | Sell |
126,280
-22,701
| -15% | -$101K | ﹤0.01% | 4957 |
|
|
2017
Q1 | $737K | Buy |
148,981
+116,861
| +364% | +$1.12M | ﹤0.01% | 4665 |
|
|
2016
Q4 | $357K | Buy |
32,120
+3,423
| +12% | +$32.2K | ﹤0.01% | 5344 |
|
|
2016
Q3 | $266K | Sell |
28,697
-17,361
| -38% | -$145K | ﹤0.01% | 5577 |
|
|
2016
Q2 | $292K | Buy |
46,058
+34,195
| +288% | +$227K | ﹤0.01% | 5357 |
|
|
2016
Q1 | $77K | Buy |
+11,863
| New | +$76.5K | ﹤0.01% | 6212 |
|
|
2015
Q4 | – | Sell |
-24,997
| Closed | -$183K | – | 7474 |
|
|
2015
Q3 | $183K | Sell |
24,997
-3,032
| -11% | -$30.9K | ﹤0.01% | 6080 |
|
|
2015
Q2 | $287K | Buy |
+28,029
| New | +$310K | ﹤0.01% | 5783 |
|
Goldman Sachs's FOMX Position: Q1 2020 in Review
Goldman Sachs sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 83,119 shares — an estimated $277K sold.
Goldman Sachs first reported a position in FOMX in Q2 2015 and held it in 18 quarters. The position peaked at $737K in Q1 2017. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- Goldman Sachs reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- Goldman Sachs sold 83,119 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $277K.
- Goldman Sachs first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 18 quarters.
- Goldman Sachs's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $737K in Q1 2017.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on Goldman Sachs's 13F filing for Q1 2020, filed 15 May 2020.